Clinical Trial Update: A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia [Phase 2]

View source ↗

Summary

Phase 2 placebo-controlled study of MR901 (talaporfin sodium with a drug-activating device) in benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• MR901 (talaporfin sodium)

Snippet

Sponsor: Light Sciences Oncology | Conditions: Benign Prostatic Hyperplasia | Phase 2 | Status: COMPLETED